Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 7/2013

01-07-2013 | Editorial Commentary

Interventional nuclear medicine

Authors: V. Ralph McCready, Sabina Dizdarevic, Mark Aplin

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 7/2013

Login to get access

Excerpt

Interventional radiology is well established and has been described as the use of minimal invasive surgery performed with the aid of simultaneous radiological imaging. It is surprising that interventional nuclear medicine has not been developed. Interventional nuclear medicine would employ a similar approach where, with the aid of a simple intervention radionuclide, treatment can be provided for benign and malignant pathology. The main difference between interventional radiology and nuclear medicine is that while the former employs an anatomical approach with radiofrequency, ultrasound and cryotherapy ablating a volume which is larger than the lesion, the nuclear medicine approach can use some aspect of physiology to locate the radiopharmaceutical within the target volume and especially any microscopic extension of the pathology. …
Literature
1.
Order SE, Siegel JA, Principato R, Zeiger LS, Johnson E, Lang P, et al. Preliminary experience of infusional brachytherapy using colloidal 32P. Ann Acad Med Singapore. 1996;25(3):347–51.PubMed
2.
Westlin JE, Andersson-Forsman C, Garske U, Linne T, Aas M, Glimelius B, et al. Objective responses after fractionated infusional brachytherapy of unresectable pancreatic adenocarcinomas. Cancer. 1997;80(12 Suppl):2743–8.PubMedCrossRef
3.
Firusian N, Dempke W. An early phase II study of intratumoral P-32 chromic phosphate injection therapy for patients with refractory solid tumors and solitary metastases 2. Cancer. 1999;85(4):980–7.PubMedCrossRef
4.
McCready VR, Heriot AG, Masoomi M, Britton A, Glees PJ, Knight M, et al. P32 interstitial therapy for unresectable carcinoma of the pancreas. J Nucl Med. 1999;40(5):984. Abstract.
5.
Botta F, Cremonesi M, Ferrari ME, Amato E, Guerriero F, Vavassori A, et al. Investigation of 90Y-avidin for prostate cancer brachytherapy: a dosimetric model for phase I-II clinical study. Eur J Nucl Med Mol Imaging. 2013. doi:10.​1007/​s00259-013-2383-1.
6.
Kratochwil C, Giesel FL, Lopez-Benitez R, Schimpfky N, Kunze K, Eisenhut M, et al. Intraindividual comparison of selective arterial versus venous 68Ga-DOTATOC PET/CT in patients with gastroenteropancreatic neuroendocrine tumors. Clin Cancer Res. 2010;16(10):2899–905.PubMedCrossRef
7.
Kratochwil C, Lopez-Benitez R, Mier W, Haufe S, Isermann B, Kauczor HU, et al. Hepatic arterial infusion enhances DOTATOC radiopeptide therapy in patients with neuroendocrine liver metastases. Endocr Relat Cancer. 2011;18(5):595–602.PubMedCrossRef
8.
Hilgard P, Hamami M, Fouly AE, Scherag A, Muller S, Ertle J, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741–9.PubMedCrossRef
9.
Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, et al. Radioembolization for hepatocellular carcinoma using yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52–64.PubMedCrossRef
10.
Hammersley PAG, Vini L, McCready VR. Intra-tumoural infusion of sources for radiotherapy of solid tumours. J Nucl Med. 1997;38(5SS):830. Abstract.
11.
Rowell NP, McCready VR, Tait D, Flower MA, Cronin B, Adams GE, et al. Technetium-99m HMPAO and SPECT in the assessment of blood flow in human lung tumours. Br J Cancer. 1989;59(1):135–41.PubMedCrossRef
12.
Royal College of Physicians. Radioiodine in the management of benign thyroid disease: clinical guidelines. Report of a working party. London: Royal College of Physicians; 2007.
13.
Metso S, Auvinen A, Huhtala H, Salmi J, Oksala H, Jaatinen P. Increased cancer incidence after radioiodine treatment for hyperthyroidism. Cancer. 2007;109(10):1972–9.PubMedCrossRef
14.
Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P. Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet. 1999;353(9170):2111–5.PubMedCrossRef
15.
Krause S, Dinkelborg LM. Intratumoral radiotherapy with targeted radiopharmaceuticals is superior to that with non-targeted tracers. Eur J Nucl Med Mol Imaging. 2005;32(1 Suppl):S207.
16.
Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, et al. Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20(8):716–31.PubMedCrossRef
17.
Cordier D, Forrer F, Bruchertseifer F, Morgenstern A, Apostolidis C, Good S, et al. Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging. 2010;37(7):1335–44.PubMedCrossRef
18.
Kneifel S, Cordier D, Good S, Ionescu MC, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance p. Clin Cancer Res. 2006;12(12):3843–50.PubMedCrossRef
19.
Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013. doi: 10.​1007/​s00259-013-2395-x.
20.
Metadata
Title
Interventional nuclear medicine
Authors
V. Ralph McCready
Sabina Dizdarevic
Mark Aplin
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 7/2013
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-013-2413-z

Other articles of this Issue 7/2013

European Journal of Nuclear Medicine and Molecular Imaging 7/2013 Go to the issue

Letter to the Editor

Reply to comment by Treglia and Bertagna: FDG PET/CT for detection of infectious endocarditis

UEMS/EBNM

Nuclear medicine training and practice in Portugal

Original Article

Metabolic response evaluated by 18F-FDG PET/CT as a potential screening tool in identifying a subgroup of patients with advanced non-small cell lung cancer for immediate maintenance therapy after first-line chemotherapy

Original Article

18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT

Original Article

Discrepant uptake of the radiolabeled norepinephrine analogues hydroxyephedrine (HED) and metaiodobenzylguanidine (MIBG) in rat hearts

Editorial

Appropriate use criteria for amyloid PET imaging cannot replace guidelines: On behalf of the European Association of Nuclear Medicine